^
    6d
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    1m
    A personalized therapeutic approach for liver cancers expressing the African-centric P47S Variant of TP53. (PubMed, Mol Cancer Res)
    We identify the microtubule targeting agents lexibulin, colchicine, and combretastatin A-4 as three compounds that bind to the colchicine-binding pocket of the a/b tubulin dimer, and which show increased efficacy in a P47S liver cancer cell line compared to parental cells with WT p53. We find evidence for an unusual mechanism underlying this increased efficacy: our data indicate that the P47S variant shows increased ability to bind to the peptidyl-prolyl isomerase PIN1; this leads to decreased PIN1-cyclin D1 complexes in P47S cells, along with increased cell cycle arrest in response to lexibulin. IMPLICATIONS: These findings support the growing literature that particular mutant forms of TP53 may have specific therapeutic vulnerabilities that can be targetable; improved understanding of these unique vulnerabilities can lead to improved understanding of p53 function.
    Journal
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
    |
    TP53 mutation • TP53 wild-type
    |
    lexibulin (CYT997)
    1m
    VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=14, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Interim analysis indicated limited efficacy
    Trial termination
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    Opdivo (nivolumab) • ofranergene obadenovec (VB-111)
    3ms
    ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Jun 2025 --> Mar 2026
    Trial primary completion date
    |
    Tookad (padeliporfin)
    4ms
    SCHEMBL4796824: a multifaceted antitumor agent targeting microtubule dynamics, DNA damage, and Wnt/β-catenin signaling in ovarian cancer cells. (PubMed, J Ovarian Res)
    SCHEMBL4796824, a BPR0L075 derivative with antitumor properties, targets tubulin's colchicine binding site and induces DNA damage response in ovarian cancer...Notably, these effects were more pronounced in c-MYC amplified SK-OV-3 cells. In summary, SCHEMBL4796824 disrupts the canonical Wnt/β-catenin signaling, inducing DNA damage, and inhibits the Wnt/β-catenin/c-MYC axis, triggering cellular senescence in a pathway-dependent manner, hinting at a novel therapeutic approach.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CHEK2 (Checkpoint kinase 2)
    |
    SB01
    4ms
    Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts (clinicaltrials.gov)
    P2, N=64, Completed, Benha University
    New P2 trial • Head-to-Head
    5ms
    Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov)
    P1, N=13, Completed, Massachusetts General Hospital | Recruiting --> Completed | N=30 --> 13 | Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    8ms
    BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. (PubMed, Cancer Immunol Immunother)
    We identified BAP1 as a potential predictive biomarker for JX-594 treatment and explored its underlying mechanisms. However, given that the study used immunodeficient models, the findings reflect tumor-intrinsic interferon responses and require further validation in immunocompetent models to assess immune microenvironment modulation and clinical relevance.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1) • IFNB1 (Interferon Beta 1) • IRF7 (Interferon Regulatory Factor 7)
    |
    Pexa-Vec (pexastimogene devacirepvec)
    9ms
    Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov)
    P1, N=30, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    11ms
    CYT997 Induces Apoptosis in Hypertrophic Scar Fibroblasts and Inhibits Scar Formation. (PubMed, Eur J Pharmacol)
    It also regulated apoptosis-related proteins poly(ADP-ribose) polymerase (PARP) and caspase-3 in HSFs. These findings suggest that CYT997 has potential as a targeted therapy for hypertrophic scars by inducing apoptosis in HSFs and reducing fibrotic activity.
    Journal • PARP Biomarker
    |
    CASP3 (Caspase 3)
    |
    lexibulin (CYT997)
    1year
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    1year
    Exploratory Evaluation of [11C]MPC6827 (clinicaltrials.gov)
    P1, N=17, Completed, Columbia University | Recruiting --> Completed | N=40 --> 17 | Trial completion date: Sep 2025 --> Jun 2024
    Trial completion • Enrollment change • Trial completion date